
Orifarm unveils 2031 strategy to accelerate growth across Europe, with significant expansion in generics1.10.2026 08:10:00 CEST | Orifarm Group A/S | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems.













